Glenmark Pharma subsidiary listing
Thursday, November 08, 2007
Divi's Labs, is a hot favorite for fund managers in Reliance and HDFC Funds. Citigroup and CLSA are optimistic on the performance of Glenmark post separation of specialty and generics business. Glenmark also unveiled a plan to structure its branded & generic businesses as separate entities, with the latter to be listed separately. The restructuring would serve Glenmark well over the long term, given the growing traction & completely diverse natures of the 2 businesses.Citigroup in its report has raised FY08, FY09 and FY10 base business EPS estimates by 16%, 10% and 15% respectively, as Glenmark raised guidance materially on the back of growing traction in key markets. It has set a new stock target price of Rs 632. Citi expects the EPS to be 21.96 and 25.04 for FY08 and FY09 respectively. CLSA has set a target price of Rs 585 on the Glenmark stock. While DSP Merrill Lynch has a neutral view on the stock.
0 Comments:
Dalal Street Business Reports
- Citigroup Downgrades Indian IT Space
- Pantaloon Retail India - Reports
- Reliance Petroleum Bubble - Book Profits
- Strong Occupancy at Kamat Hotels - BUY
- Vinati Organics Small Cap Recommendations
- Jai Hind Projects, Initiating Coverage
- Book Profits Punj Lloyd + Powergrid
- Accumulate Voltas - Cooling business - Hot results...
- ABB is getting expensive
- BUY Bharat Forge
